Copyright © BusinessAMBE 2023

Biocartis will be delisted. The biotech company announces that there will probably be nothing left for shareholders.

Biocartis has been in bad shape for some time, and that is obviously reflected in its share price. Since the IPO in 2015, the price has dropped 97.3 percent from about 10.6 to 0.3 euros.

In the news: Biocartis is undertaking a sweeping debt restructuring to force a relaunch. That intervention will take the ailing company off the stock market.

  • The biotech company announces in a press release that bondholders will convert 132 million in receivables into shares. In addition, they will inject an additional 40 million euros into the company. This operation should ensure that Biocartis has sufficient cash until 2024. The aim is to break even operationally by then.
    • According to Roger Moody, CEO of Biocartis, a combination of difficult market conditions, the balance sheet and historical cash burn make it impossible to obtain outside financing.
    • The transaction is expected to close by the end of the year, depending on receipt of certain regulatory approvals.
  • Shareholders will have a bitter pill to swallow. Management informs that they will likely receive nothing at the time of liquidation.
  • Furthermore, unsecured convertible bonds with a coupon of 4 percent and maturing in 2027 will be written down to zero.
  • "While disappointing to shareholders and certain bondholders, this transaction is necessary," Moody said. "I am confident that under the new recapitalized holding company and in conjunction with the operational reorganization now being completed, the surviving company will be able to continue on its path to financial health and sustainability."
  • According to the company, this operation will have no impact on customers, suppliers, partners and employees.

Some results

Details: Biocartis also shared half-year results on Tuesday

  • Sales (product-related) reached 23.5 million euros, which is 10 percent more than in the same period last year.
  • The company reported 22 percent growth in oncology cartridge revenues, a 40 percent gross margin on product sales and a 20 percent improvement in EBITDA to -14.5 million euros.

(nd)

© The Content Exchange, source News